CSL-112 increases cholesterol efflux in humans

The product, a reconstituted formulation of apoA1, rapidly raises HDL levels and promotes reverse cholesterol transport. It is being positioned as a new therapeutic approach to quickly lower the atherosclerosis burden in an attempt to reduce cardiovascular events in the initial days after an ACS.

via The Heart